|Videos|March 20, 2023
Disease Progression After Adjuvant Pembrolizumab Therapy for RCC
The panel shares how they would treat a patient with advanced RCC after disease progression on adjuvant pembrolizumab.
Advertisement
Episodes in this series
Advertisement
Related to this article
Ayal Aizer, MD, MHS, explains why fractionated SRS outperformed single-fraction SRS for surgical bed control in Alliance A071801.
Andy Liao, MD, discusses KRAS-targeted strategies, molecular profiling, multidisciplinary care, and FGFR2 inhibitor sequencing in cholangiocarcinoma.
“To me, the biggest differentiator might be how the patient wants to experience care,” said Krish Patel, MD, on treatment options for patients with lymphoma.
Ayal Aizer, MD, MHS, says Alliance A071801 supports fractionated SRS as standard after resection, with comparable radiation necrosis rates.
Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center.
A personalized ctDNA assay demonstrated 100% specificity but limited sensitivity for detecting recurrence after liver transplantation in HCC and CCA.
The FDA cleared the SpaceOAR Flex System, a hydrogel spacer used during prostate cancer radiotherapy, in a 510(k) supported by the HYDROSPACE trial.
Phase 2 ASPEN-06 data showed higher response rates with evorpacept added to trastuzumab, ramucirumab, and paclitaxel in HER2-positive gastric cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Radiation May Improve Tolerability in Cholangiocarcinoma
2
Distal Extrahepatic Cholangiocarcinoma May Gain From Neoadjuvant Radiation
3
Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM
4
Hydrogel Spacer Receives FDA 510(k) Clearance for Prostate Cancer Radiotherapy
5